annual cash & cash equivalents:
$370.70M-$196.15M(-34.60%)Summary
- As of today (September 16, 2025), TVTX annual cash & cash equivalents is $370.70 million, with the most recent change of -$196.15 million (-34.60%) on December 31, 2024.
- During the last 3 years, TVTX annual cash & cash equivalents has fallen by -$182.18 million (-32.95%).
- TVTX annual cash & cash equivalents is now -34.60% below its all-time high of $566.85 million, reached on December 31, 2023.
Performance
TVTX Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$319.54M-$2.71M(-0.84%)Summary
- As of today (September 16, 2025), TVTX quarterly cash & cash equivalents is $319.54 million, with the most recent change of -$2.71 million (-0.84%) on June 30, 2025.
- Over the past year, TVTX quarterly cash & cash equivalents has dropped by -$5.86 million (-1.80%).
- TVTX quarterly cash & cash equivalents is now -49.65% below its all-time high of $634.64 million, reached on September 30, 2023.
Performance
TVTX quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
TVTX Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -34.6% | -1.8% |
| 3 y3 years | -33.0% | -42.2% |
| 5 y5 years | - | -30.1% |
TVTX Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -34.6% | at low | -49.6% | +15.2% |
| 5 y | 5-year | -34.6% | +2.5% | -49.6% | +15.2% |
| alltime | all time | -34.6% | >+9999.0% | -49.6% | >+9999.0% |
TVTX Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $319.54M(-0.8%) |
| Mar 2025 | - | $322.24M(-13.1%) |
| Dec 2024 | $370.70M(-34.6%) | $370.70M(+33.6%) |
| Sep 2024 | - | $277.44M(-14.7%) |
| Jun 2024 | - | $325.40M(-26.2%) |
| Mar 2024 | - | $441.04M(-22.2%) |
| Dec 2023 | $566.85M(+25.9%) | $566.85M(-10.7%) |
| Sep 2023 | - | $634.64M(+29.2%) |
| Jun 2023 | - | $491.34M(-12.5%) |
| Mar 2023 | - | $561.51M(+24.7%) |
| Dec 2022 | $450.25M(-18.6%) | $450.25M(-11.1%) |
| Sep 2022 | - | $506.33M(-8.5%) |
| Jun 2022 | - | $553.17M(-8.3%) |
| Mar 2022 | - | $603.39M(+9.1%) |
| Dec 2021 | $552.88M(+52.9%) | $552.88M(+0.3%) |
| Sep 2021 | - | $551.18M(+5.4%) |
| Jun 2021 | - | $522.79M(+0.4%) |
| Mar 2021 | - | $520.87M(+44.1%) |
| Dec 2020 | $361.59M | $361.59M(-20.8%) |
| Sep 2020 | - | $456.27M(-0.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2020 | - | $457.38M(+28.3%) |
| Mar 2020 | - | $356.46M(+18.6%) |
| Dec 2017 | $300.63M(+633.2%) | $300.63M(+35.2%) |
| Dec 2016 | $41.00M(+8.5%) | - |
| Mar 2016 | - | $222.34M(+488.1%) |
| Dec 2015 | $37.80M(+107.7%) | $37.80M(-73.1%) |
| Sep 2015 | - | $140.60M(+10.1%) |
| Jun 2015 | - | $127.75M(+6.3%) |
| Mar 2015 | - | $120.17M(+560.2%) |
| Dec 2014 | $18.20M(+203.5%) | $18.20M(-29.6%) |
| Sep 2014 | - | $25.86M(-35.2%) |
| Jun 2014 | - | $39.88M(+979.2%) |
| Mar 2014 | - | $3.70M(-38.4%) |
| Dec 2013 | $6.00M(>+9900.0%) | $6.00M(-55.3%) |
| Sep 2013 | - | $13.41M(+4580.6%) |
| Jun 2013 | - | $286.50K(-88.6%) |
| Mar 2013 | - | $2.50M(>+9900.0%) |
| Dec 2012 | $11.40K(+185.0%) | - |
| Nov 2011 | - | $3900.00(0.0%) |
| Aug 2011 | - | $3900.00(-2.5%) |
| Feb 2011 | $4000.00 | $4000.00 |
FAQ
- What is Travere Therapeutics, Inc. annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Travere Therapeutics, Inc.?
- What is Travere Therapeutics, Inc. annual cash & cash equivalents year-on-year change?
- What is Travere Therapeutics, Inc. quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Travere Therapeutics, Inc.?
- What is Travere Therapeutics, Inc. quarterly cash & cash equivalents year-on-year change?
What is Travere Therapeutics, Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of TVTX is $370.70M
What is the all time high annual cash & cash equivalents for Travere Therapeutics, Inc.?
Travere Therapeutics, Inc. all-time high annual cash & cash equivalents is $566.85M
What is Travere Therapeutics, Inc. annual cash & cash equivalents year-on-year change?
Over the past year, TVTX annual cash & cash equivalents has changed by -$196.15M (-34.60%)
What is Travere Therapeutics, Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of TVTX is $319.54M
What is the all time high quarterly cash & cash equivalents for Travere Therapeutics, Inc.?
Travere Therapeutics, Inc. all-time high quarterly cash & cash equivalents is $634.64M
What is Travere Therapeutics, Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, TVTX quarterly cash & cash equivalents has changed by -$5.86M (-1.80%)